On August 18, Revolution Medicines, Inc. rose 5.05% in regular trading, trading at approximately $214.4 per share with turnover of $1.44 billion, extending its recent upward trajectory.

The sustained rally is attributed to the continued market digestion of a multi-part collaboration agreement with BeiGene announced on August 10. Under the deal, BeiGene secured exclusive development and commercialization rights to four clinical-stage RAS(ON) inhibitors — daraxonrasib, zoldonrasib, elironrasib, and RMC-5127 — in select Asian markets. BeiGene will also fund a global registrational Phase 3 study. Notably, daraxonrasib demonstrated a median overall survival of 13.2 months versus 6.7 months for chemotherapy in a Phase 3 pancreatic cancer trial, and zoldonrasib has received FDA Breakthrough Therapy Designation. The FDA also accepted a New Drug Application for daraxonrasib in July, while the European Medicines Agency initiated a rolling review, reinforcing the pipeline's regulatory momentum.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)